GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NeurAxis Inc.
NeurAxis develops a medical device for nerve stimulation to treat functional abdominal pain in children. Its stock price reflects its struggle to commercialize and gain widespread acceptance for its niche product.
Share prices of companies in the market segment - Neuro
NeurAxis is a medical company that has developed a non-invasive neurostimulation device used to treat functional abdominal pain in children. We've categorized it under the "Neurology" category. The chart below shows how the market is evaluating new approaches to treating chronic pain.
Broad Market Index - GURU.Markets
NeurAxis is a medical company that has developed a non-invasive neurostimulation device used to treat functional abdominal pain in children. Its unique technology makes it part of the GURU.Markets index. The chart below compares its performance with the market.
Change in the price of a company, segment, and market as a whole per day
NRXS - Daily change in the company's share price NeurAxis Inc.
For NeurAxis, Inc., a neuromedical company, daily price change is a measure of high volatility. It reflects the market's reaction to clinical trial data and regulatory decisions, and is a key parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Neuro
NeurAxis, Inc. is a medical technology company. This chart illustrates the high volatility of the MedTech industry. Comparing it to NRXS, which focuses on neurostimulation, helps us understand how its innovative products contribute to its volatility.
Daily change in the price of a broad market stock, index - GURU.Markets
NeurAxis develops medical devices for neuromodulation in the treatment of functional pain. The stock price of this medtech company depends on the adoption of its technology in medical practice. Such unique stories are part of a larger market, whose overall volatility you can see.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NeurAxis Inc.
NeurAxis, Inc.'s year-over-year performance tells the story of its commercialization of its technology for treating functional abdominal pain in children. Its market cap growth over the past 12 months reflects its success in advancing its non-invasive nerve stimulator, which offers a new, drug-free option for treating this common and complex condition.
Annual dynamics of market capitalization of the market segment - Neuro
NeurAxis, Inc. is a medical device company that has developed a non-invasive neurostimulation technology. This chart shows how its innovative yet niche technology and efforts to gain acceptance within the medical community are impacting its performance in the medical device sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NeurAxis, with its device for treating functional pain, is a growth story in medicine. Its stock price is driven not by the economy, but by its success in commercialization and securing insurance coverage. The chart reflects the potential of this breakthrough technology in a huge market, regardless of the economic climate.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NeurAxis Inc.
NeurAxis is a medical device company commercializing neurostimulation devices. Its monthly performance reflects progress in securing insurance approvals and growing sales of its devices for treating functional abdominal pain in children.
Monthly dynamics of market capitalization of the market segment - Neuro
NeurAxis, Inc. develops and markets medical neurostimulation devices aimed at treating functional abdominal pain in children. This is a highly specialized niche. The dynamics of the medical technology sector demonstrate a general trend toward non-drug therapies. NeurAxis strives to make its technology the standard in pediatric gastroenterology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NeurAxis, Inc. is a medical technology company commercializing non-invasive neurostimulation devices for the treatment of functional abdominal pain in children. Its business operates at the intersection of neurology and gastroenterology. The broader market graph allows us to assess the extent to which its innovative technology has gained acceptance among physicians, regardless of the general sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NeurAxis Inc.
NeurAxis, a developer of non-invasive therapy for functional abdominal pain in children, is extremely sensitive to medical and insurance news. Weekly stock price movements reflect insurance company coverage decisions, data on the implementation of its technology in pediatric practice, and new clinical publications.
Weekly dynamics of market capitalization of the market segment - Neuro
NeurAxis, like other early-stage MedTech companies, is riding the general speculative wave of interest in the sector. Investor appetite for risk and funding news in the industry create broad ripples. The chart will show whether NRXS follows this general trend or whether specific medical device news is creating its own momentum.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NeurAxis, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on FDA decisions and commercialization success. The chart below clearly demonstrates how NRXS shares can live their own life, separate from the broader market.
Market capitalization of the company, segment and market as a whole
NRXS - Market capitalization of the company NeurAxis Inc.
The NeurAxis chart tells the story of drug-free treatments for neurological disorders. The market cap of this company, which develops nerve stimulation devices, reflects investor hopes for its technology. Its dynamics reflect the market's assessment of its ability to secure regulatory approval and convince doctors of the effectiveness of its approach.
NRXS - Share of the company's market capitalization NeurAxis Inc. within the market segment - Neuro
NeurAxis develops and markets neurostimulation systems for the treatment of functional abdominal pain in children. Its market share in the neurological equipment sector reflects its leadership in this niche. The graph shows how its drug-free therapy is becoming the standard in pediatric gastroenterology.
Market capitalization of the market segment - Neuro
NeurAxis develops medical neurostimulation devices aimed at treating functional gastrointestinal diseases in children. The chart below shows the market capitalization of the neuroscience sector, where innovative technologies offer new approaches to treating chronic pain.
Market capitalization of all companies included in a broad market index - GURU.Markets
NeurAxis has developed a non-invasive neurostimulation device for the treatment of functional abdominal pain in adolescents. Its market cap reflects a new approach to chronic pain treatment. The chart below shows the economic weight of companies working in this field.
Book value capitalization of the company, segment and market as a whole
NRXS - Book value capitalization of the company NeurAxis Inc.
NeurAxis's book value is derived from its medical device and intellectual property. The company's foundation is its patents and inventory of the IB-Stim system, a non-invasive nerve stimulator for the treatment of functional abdominal pain in adolescents. The chart below shows how the company is building the material base for commercializing its unique medical device.
NRXS - Share of the company's book capitalization NeurAxis Inc. within the market segment - Neuro
NeurAxis, Inc. develops medical devices for neuroscience. Its tangible assets include R&D centers and production lines. The S_BCap_Seg chart shows its share of the physical infrastructure of the neurotechnology sector.
Market segment balance sheet capitalization - Neuro
NeurAxis develops medical devices for neurostimulation. The creation of such devices requires investment in R&D and certified manufacturing. The book value chart shows how these investments in tangible and intangible assets form the basis for its growth in the medical technology sector.
Book value of all companies included in the broad market index - GURU.Markets
NeurAxis's balance sheet is a manufacturing base for non-drug treatments. The company's assets include the production facilities for its neurostimulation devices for the treatment of functional abdominal pain in children. This represents capital invested in the creation of an innovative and safe alternative to traditional medications.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NeurAxis Inc.
NeurAxis develops medical devices for the treatment of functional abdominal pain associated with disorders of the gut-brain connection. The company's book value is small. Its market capitalization is based on its patented neurostimulation technology and its potential in the chronic disease market.
Market to book capitalization ratio in a market segment - Neuro
NeurAxis develops medical devices for the treatment of functional abdominal pain in children. Its value lies in its patented technology. The chart shows the market premium for its innovative non-drug solution compared to the book value of its assets, reflecting the potential of this niche market.
Market to book capitalization ratio for the market as a whole
NeurAxis develops and markets neurostimulation devices for the treatment of functional abdominal pain in children. The company's value lies in its patented technology. The chart illustrates the premium investors are willing to pay for innovative, drug-free treatments, valuing the company above its tangible assets.
Debts of the company, segment and market as a whole
NRXS - Company debts NeurAxis Inc.
NeurAxis, a company developing medical devices for the treatment of neurological disorders, uses debt for commercialization and research. This chart shows how the company finances the commercialization of its already approved products and clinical trials to expand their indications.
Market segment debts - Neuro
NeurAxis develops and commercializes medical devices for non-invasive neurostimulation. Bringing new medical devices to market is a capital-intensive process, requiring significant expenditures on clinical trials, approvals, and marketing. This chart shows how the company manages its financial resources on its path to profitability.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NeurAxis Inc.
NeurAxis specializes in developing medical devices for the treatment of functional gastrointestinal disorders. This chart shows the proportion of its funding that comes from debt. For a company bringing an innovative medical product to market, debt leverage is an indicator of its confidence in the commercial success of the technology and the associated risks.
Market segment debt to market segment book capitalization - Neuro
NeurAxis develops medical devices for the treatment of functional gastrointestinal disorders, working at the intersection of neurology and gastroenterology. This chart for the medical device sector shows how much capital the industry attracts for R&D and commercialization. This helps assess how typical the company's financial strategy is for this innovative niche.
Debt to book value of all companies in the market
NeurAxis develops medical devices for the treatment of functional gastrointestinal disorders by targeting the nervous system. This chart, which reflects the overall debt-to-book value ratio of the market, is important for understanding the investment climate in the medical device sector. The availability of debt capital is a key factor in funding clinical trials and bringing a product to market.
P/E of the company, segment and market as a whole
P/E - NeurAxis Inc.
NeurAxis develops and markets neurostimulation devices for the treatment of functional abdominal pain in children. This chart reflects the potential of non-drug therapies. Its value reflects how investors view the prospects for this technology's adoption in medical practice and its potential to become a standard of care for a specific patient group.
P/E of the market segment - Neuro
NeurAxis is in the medical device sector. This chart shows the average price-to-earnings ratio (P/E) for this innovative industry. Comparing the company's P/E to this ratio allows us to assess how highly the market values its neurostimulation technology compared to other medical devices and treatments on the market.
P/E of the market as a whole
NeurAxis develops and commercializes non-invasive neurostimulation devices for the treatment of functional abdominal pain in adolescents. The company's success depends on the adoption of its technology in clinical practice. This chart shows the current sentiment in the medical device sector. It helps understand whether the market sees potential for NeurAxis to expand into new indications and how it evaluates its niche position.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NeurAxis Inc.
NeurAxis develops and commercializes non-invasive neurostimulation devices for the treatment of functional abdominal pain in children. The chart shows market expectations for future revenue, which depend on the expansion of this technology and approval for other conditions. This is a bet on innovation in non-drug therapies.
%20P%2FE%20NeurAxis%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NeurAxis-Inc.&v=1772615703683 "Chart of the company's future (projected) P/E NeurAxis Inc.")
Future (projected) P/E of the market segment - Neuro
NeurAxis has developed a non-invasive neurostimulation system for the treatment of functional abdominal pain in children associated with irritable bowel syndrome. This chart shows how its future revenue expectations compare to the industry average, reflecting its potential to offer a non-drug treatment for this condition.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772615703769 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
NeurAxis develops and commercializes non-invasive neurostimulation devices for the treatment of functional abdominal diseases, particularly in children. The company's success depends on the implementation of its technology in clinical practice. This is a story of healthcare innovation unrelated to general economic cycles.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772615703806 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NeurAxis Inc.
NeurAxis, Inc. develops and commercializes medical neurostimulation devices designed to treat functional abdominal pain in adolescents. The company's revenue depends on the acceptance of its technology by physicians and patients, as well as reimbursement from insurance companies. This chart shows how innovations in non-drug therapies impact financial performance.
Profit of companies in the market segment - Neuro
NeurAxis, Inc. is a medical technology company that has developed a drug-free nerve stimulation device for the treatment of functional abdominal pain in children. This chart shows the profitability of the neurology segment. NeurAxis's success depends on the acceptance of its innovative therapy by physicians and insurance companies, which could create a new market niche and impact overall profitability.
Overall market profit
NeurAxis, Inc. develops and markets medical neurostimulation devices designed to treat functional abdominal pain in adolescents. Demand for these innovative treatments depends on their acceptance by the medical community and insurance companies. This chart illustrates the overall economic backdrop against which NeurAxis is carving out its niche in the high-tech medical field.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NeurAxis Inc.
NeurAxis develops and commercializes neurostimulation devices aimed at treating functional abdominal pain in children. This chart reflects analysts' expectations for future revenue, which depend on physician adoption of this innovative technology. It demonstrates the market's confidence in the potential of non-drug treatments for chronic diseases.
%20profit%20of%20the%20company%20NeurAxis%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NeurAxis-Inc.&v=1772615703916 "Graph of future (projected) profit of the company NeurAxis Inc.")
Future (predicted) profit of companies in the market segment - Neuro
NeurAxis, Inc. develops and commercializes non-invasive neuromodulation therapies for the treatment of functional gastrointestinal disorders in children. This chart shows revenue projections for the neuroscience sector. It reflects expectations for innovative medical devices offering alternatives to drug treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772615703929 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
NeurAxis develops medical devices for the treatment of functional gastrointestinal disorders. Demand for new medical technologies depends on clinic budgets and patient purchasing power. The overall profit forecast shown in the graph is influenced by these factors. Economic growth accelerates innovation, while recessions slow it down.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772615703963 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NeurAxis Inc.
NeurAxis, Inc. develops neurostimulation devices for the treatment of functional abdominal diseases. A P/S for a company at the commercialization stage reflects how investors view the adoption of its innovative technology by physicians and patients, as well as its potential to change treatment standards.
P/S market segment - Neuro
NeurAxis, Inc. develops and commercializes non-invasive neurostimulation devices for the treatment of functional abdominal pain in children associated with irritable bowel syndrome. This chart illustrates how the market views their innovative approach to chronic pain treatment and the commercialization potential of their unique medical technology.
P/S of the market as a whole
NeurAxis develops and commercializes neurostimulation devices aimed at treating functional abdominal pain in children. Revenue is dependent on physician acceptance of the technology. This chart illustrates the average revenue estimate, allowing one to estimate the market premium for innovative pediatric medical devices.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NeurAxis Inc.
NeurAxis develops and commercializes non-invasive neurostimulation devices for the treatment of functional abdominal pain in children. This chart reflects investor expectations for future revenue from this innovative medical technology, based on its potential to become a standard of care for certain pediatric conditions.
%20P%2FS%20NeurAxis%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NeurAxis-Inc.&v=1772615704042 "The graph of the company's future (projected) P/S NeurAxis Inc.")
Future (projected) P/S of the market segment - Neuro
NeurAxis, Inc. is a medical technology company that has developed a drug-free device for the treatment of functional abdominal pain in children with irritable bowel syndrome. This chart shows how the market estimates future sales of its innovative device. It compares it to other companies in the neuroscience sector, highlighting the potential of its unique technology.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772615704062 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
NeurAxis develops and commercializes non-invasive neurostimulation devices for the treatment of functional abdominal pain, such as irritable bowel syndrome. This chart shows aggregate market expectations for future revenue, and NeurAxis illustrates how new approaches in medtech can create alternatives to drugs and shape new markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772615704069 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NeurAxis Inc.
NeurAxis, Inc. is a commercial medical technology company. Its revenue, reflected in this chart, is generated by sales of an innovative neurostimulation device designed to treat functional abdominal pain associated with disorders such as irritable bowel syndrome in adolescents.
Sales of companies in the market segment - Neuro
NeurAxis develops and commercializes medical devices for neuromodulation. This chart shows the revenue from sales of its flagship product. It allows investors to track sales trends and assess the company's success in bringing its innovative technology for the treatment of functional pain to market.
Overall market sales
NeurAxis, Inc. develops medical devices for the treatment of functional gastrointestinal disorders. The need for such treatments is determined by patient health, not economics. This timeline is irrelevant to NeurAxis, whose success depends on the clinical effectiveness of its technology and its acceptance by the medical community.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NeurAxis Inc.
NeurAxis develops and commercializes non-invasive neurostimulation devices for the treatment of functional abdominal pain in children. The company's revenue forecast depends on the adoption of its technology in pediatric practice. This chart shows analyst expectations for the commercialization of this innovative medical device.
%20sales%20of%20the%20company%20NeurAxis%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NeurAxis-Inc.&v=1772615704156 "Schedule of future (projected) sales of the company NeurAxis Inc.")
Future (projected) sales of companies in the market segment - Neuro
NeurAxis develops and markets medical devices for the treatment of functional abdominal pain in children. This chart shows projected revenue for the neurological medical device segment. It helps estimate the potential demand for non-drug treatments for chronic conditions, which is key to the implementation of NeurAxis's innovative technology in pediatric practice.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772615704175 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
NeurAxis develops and markets medical neurostimulation devices designed to treat functional abdominal pain in adolescents. Demand for its products depends on physician acceptance of the technology and patient affordability. This graph of overall economic expectations reflects the financial health of consumers, influencing their ability to afford innovative treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772615704220 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NeurAxis Inc.
NeurAxis develops and commercializes medical neurostimulation devices aimed at treating functional gastrointestinal diseases. This graph shows the path to profitability in medtech. The ability to generate profit depends on regulatory approval, insurance reimbursement, and the expansion of technology adoption.
Market segment marginality - Neuro
NeurAxis develops and commercializes innovative neurostimulation devices for the treatment of functional abdominal pain in adolescents. This chart illustrates the average profitability in the neurotechnology sector. It provides context for understanding the market share and profitability NeurAxis could achieve with its unique technology if it achieves widespread adoption.
Market marginality as a whole
NeurAxis, Inc. develops and commercializes neurostimulation devices for the treatment of functional abdominal pain in adolescents. This total market revenue graph does not reflect NeurAxis's business, which is dependent on regulatory approval, physician acceptance, and expanded indications for its unique technology.
Employees in the company, segment and market as a whole
Number of employees in the company NeurAxis Inc.
NeurAxis develops and commercializes medical devices for neurostimulation. The company's team combines expertise in engineering, medicine, and commercialization. Growth in this graph may indicate expansion of the sales and marketing team after receiving regulatory approvals, a key step toward increasing revenue.
Share of the company's employees NeurAxis Inc. within the market segment - Neuro
NeurAxis, Inc. develops and commercializes non-invasive neurostimulation devices for the treatment of functional gastrointestinal diseases, particularly in children. This chart illustrates its unique medical niche. It reflects the proportion of medical engineers and clinicians working at the intersection of neurology and gastroenterology that comprise this innovative company.
Number of employees in the market segment - Neuro
NeurAxis, Inc. develops and commercializes innovative neurostimulation devices for the treatment of functional gastrointestinal diseases. This chart illustrates employment in neuroscience. The growing number of specialists in this field reflects the search for non-drug treatments for chronic conditions, creating a market for NeurAxis's advanced therapeutic technologies.
Number of employees in the market as a whole
NeurAxis, Inc. develops medical devices to treat functional abdominal pain in adolescents associated with irritable bowel syndrome. The development of medical technology is creating new jobs in high-tech fields. This chart illustrates the overall employment trend, driven by innovative companies changing treatment approaches.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NeurAxis Inc. (NRXS)
NeurAxis, Inc. develops medical devices for neurology. The company's value lies in its patents and clinical data. This chart illustrates how the market values this intellectual capital. The high employee-to-employee ratio reflects investors' bet that the company's technology will become a new standard of care.
%20of%20the%20company%20NeurAxis%20Inc.%20(NRXS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NeurAxis-Inc.-NRXS&v=1772615704574 "Chart of market capitalization per employee (in thousands of dollars) of the company NeurAxis Inc. (NRXS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
NeurAxis develops medical devices for neurostimulation. The company's value is concentrated in its patents and technologies. Its market capitalization per employee is an indicator of how the market views the potential of its unique developments. A high value relative to the sector may indicate the expectation of a breakthrough in the treatment of neurological disorders.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772615704591 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
NeurAxis develops and commercializes neurostimulation devices for the treatment of functional abdominal pain in adolescents. This is an innovative medical technology. This chart shows how the market evaluates the potential of a small team to create and commercialize a new standard of care for a specific patient group.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772615704630 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NeurAxis Inc. (NRXS)
NeurAxis is a medical company commercializing its neuromodulation technology (IB-Stim) for treating chronic pain in adolescents. This is the "go-to-market" stage. This graph, likely negative, shows how much the company spends on each employee (especially in sales and marketing) to convince doctors and patients of the effectiveness of its therapy.
%20Chart%20NeurAxis%20Inc.%20(NRXS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NeurAxis-Inc.-NRXS&v=1772615704667 "Company Profit Per Employee (in thousands of dollars) Chart NeurAxis Inc. (NRXS)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
NeurAxis develops and commercializes medical neurostimulation devices designed to treat functional abdominal pain in adolescents. This graph illustrates the commercial potential of their unique technology. It shows how efficiently the company generates revenue, which is an indicator of the market demand for their product and the value of their intellectual property.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772615704683 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
NeurAxis, Inc. develops medical devices for neurostimulation, specifically for the treatment of functional abdominal pain in children. This metric reflects the ratio of high R&D and marketing expenses (for reaching physicians) to current sales. This trend demonstrates how successfully the company is scaling sales of its innovative device using its team's resources.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772615704715 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NeurAxis Inc. (NRXS)
NeurAxis, Inc., a company developing medical devices for neurology, is in the commercialization phase. This chart shows how successfully its technology is penetrating the market. Increasing revenue per employee will mean product acceptance by the medical community and expanded sales, which is critical for a young medical company.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NeurAxis-Inc.-NRXS&v=1772615704826 "Sales chart per company employee NeurAxis Inc. (NRXS)")
Sales per employee in the market segment - Neuro
NeurAxis, Inc. (NRXS) is a medical device company that has developed a non-invasive nerve stimulation device (IB-Stim) for the treatment of functional abdominal pain in adolescents. This chart shows the average revenue per employee in the medical device segment. Comparing NRXS to this benchmark demonstrates how effectively their team is commercializing this innovative technology for a niche market.
Sales per employee for the market as a whole
NeurAxis (NRXS) is a medical technology company developing neurostimulation devices (for example, for treating gastrointestinal disorders in children). The company is in the commercialization phase. This metric demonstrates how successfully their sales team is promoting this innovative technology to doctors and hospitals, converting R&D investments into real revenue.
Short shares by company, segment and market as a whole
Shares shorted by company NeurAxis Inc. (NRXS)
NeurAxis is a company that produces a medical device (IB-Stim) that uses neurostimulation to treat functional abdominal pain in adolescents (such as IBS). This chart shows that investors are skeptical of its commercial success. Bears are betting that the company will fail to convince doctors and insurance companies of the effectiveness of this niche technology.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NeurAxis-Inc.-NRXS&v=1772615705015 "Short Shares Chart for the Company NeurAxis Inc. (NRXS)")
Shares shorted by market segment - Neuro
NeurAxis (NRXS) is the company behind IBStim, a non-invasive neurostimulator for treating chronic pain in adolescents. This chart highlights the pessimism in the neurotech sector. The rise in short positions across the industry indicates that investors doubt the commercial success of such devices. They are betting that doctors won't prescribe them and insurance companies won't pay for them. For NRXS, this is the main barrier in the market.
Shares shorted by the overall market
NeurAxis develops medical neurostimulation devices aimed at treating functional abdominal pain in children. It's a highly specialized medtech company. This chart reflects a common fear. When investors are pessimistic, they doubt the ability of small companies to commercialize niche products. They fear slow market adoption and problems obtaining insurance coverage for NRXS.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NeurAxis Inc. (NRXS)
NeurAxis (NRXS) specializes in neurostimulation for the treatment of functional abdominal pain, particularly in children. It's a highly specialized medical technology. This chart measures the strength of price movements. It helps identify when stocks are "overheated" (above 70) due to regulatory news or "oversold" (below 30) due to profit-taking.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NeurAxis-Inc.-NRXS&v=1772615705098 "RSI 14 indicator chart for the company's stock NeurAxis Inc. (NRXS)")
RSI 14 Market Segment - Neuro
NeurAxis (NRXS) developed Auris, a non-invasive vagus nerve stimulation device used to treat functional abdominal pain in children. This chart measures the pulse of the Neuroscience/Medical Equipment sector. It helps distinguish NeurAxis's unique commercial success from the overall overheated or oversold medtech sector.
RSI 14 for the overall market
NeurAxis (NRXS) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NRXS (NeurAxis Inc.)
NeurAxis (NRXS) is the maker of IB-Stim, a medical device (neurostimulator) approved by the FDA for the treatment of abdominal pain in adolescents with IBS (irritable bowel syndrome). This chart shows the average price target from analysts assessing the adoption rate of this non-drug therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NRXS-NeurAxis-Inc.&v=1772615705136 "A chart showing analyst consensus forecasts for the expected stock price. NRXS (NeurAxis Inc.)")
The difference between the consensus estimate and the actual stock price NRXS (NeurAxis Inc.)
NeurAxis is a medical technology company that developed IB-Stim, a non-invasive device (a nerve stimulator placed behind the ear) for treating functional abdominal pain in adolescents. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in this non-drug therapy and its commercial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NRXS-NeurAxis-Inc.&v=1772615705202 "A chart showing the difference between the consensus forecast and the actual stock price. NRXS (NeurAxis Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
NeurAxis (NRXS) is a medical company that developed the IB-Stim, a wearable neurostimulation device (on the ear) for treating functional abdominal pain in adolescents. This chart shows general expectations for the neuroscience sector. It reflects whether experts believe in the market for non-drug pain therapy.
Analysts' consensus forecast for the overall market share price
NeurAxis (NRXS) is a medical technology company that treats abdominal nerves. They have developed a non-invasive stimulator (IB-Stim) that uses the ear nerves to treat IBS (irritable bowel syndrome) in adolescents. This chart shows the overall risk appetite, reflecting the market's willingness to fund companies whose breakthrough medical technologies are changing the standard of care.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NeurAxis Inc.
NeurAxis (NRXS) is a MedTech company that treats stomach problems through the ear. Their flagship product (IBStim) is a non-invasive neurostimulator (worn behind the ear) that is FDA-approved for the treatment of irritable bowel syndrome (IBS) in adolescents. This chart summarizes their adoption history, reflecting their (slow) success in convincing doctors and insurers to adopt their innovative technology.
AKIMA Market Segment Index - Neuro
NeurAxis (NRXS) is a medical technology company and a pioneer in neuromodulation. Their flagship product, IB-Stim, is a drug-free device for the treatment of abdominal pain associated with IBS in adolescents. This chart shows the average index value for the segment, helping investors assess how this innovative, drug-free strategy compares to the market average.
The AKIM Index for the overall market
NeurAxis is a medtech company that developed the PENFS technology for the treatment of chronic abdominal pain in children (functional gastrointestinal disorders). This chart, reflecting the market average, provides background information. It helps assess how this pediatric-focused niche company stacks up against overall macroeconomic trends.
